HMN 2025: What insights into the roles of proteins in Duchenne muscular dystrophy

A new study has shed light on the complex interactions between dystrophin, a protein essential for muscle stability, and its partner protein dystrobrevin, opening new avenues for understanding and treating Duchenne muscular dystrophy (DMD).

Published in the December issue of Journal of Biological Chemistryresearchers characterize the mysterious C-terminal (CT) domain of dystrophin and its role in stabilizing cell membranes in various tissues.

DMD, a serious genetic disease that causes muscle weakness and shortens lifespan, results from mutations in the gene encoding dystrophin. Although current treatments can extend the lifespan of patients, their high cost and limited effectiveness highlight the urgent need for broader therapeutic approaches.

“This research highlights the complex dynamics of interactions between dystrophin and dystrobrevin, providing critical information that could inform future treatment development,” said Krishna Mallela, professor of pharmaceutical sciences in the Skaggs School of Pharmacy and of Pharmaceutical Sciences from the University of Colorado and lead author of the study. “By understanding how these proteins function differently in various tissues, we are one step closer to designing treatments that target the root causes of DMD.”

The study reveals that the CT domain of dystrophin interacts differently with the two major isoforms of dystrobrevin, which bind to dystrophin. Variations in the amino acid composition of dystrobrevin proteins result in differences in binding affinity and interaction patterns, influencing the stability of the dystrophin-associated protein complex in tissues, a key indication of DMD.

These findings offer a molecular explanation for the many symptoms experienced by DMD patients, which extend beyond skeletal muscles to affect organs such as the heart and brain.

“This discovery is exceptional for advancing DMD care because, although there have been advances in therapies, they have been approved out of desperation. We need to get to the root of things to really focus on effective treatments,” Mallela explains. “Just like a car engine, how can you repair a car without understanding how the car engine works?”